Enter your terms above and click the 'Search' button.

Showing articles 0 to 4 of 4 Filter Applied: risk-benefit assessment (Click to remove) Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007 Drugs Associated with Ischemic Stroke Stroke 52:e646-e659, Marto, J.P.,et al, 2021 Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies JAMA Neurol 77:184-191, Luna, G.,et al, 2020 Infliximab and Reactivation of Cerebral Toxoplasmosis NEJM 353:1530-1531, Callegari,P.E., 2005 Showing articles 0 to 4 of 4